Eupraxia Pharmaceuticals (EPRX) AI Stock Analysis

• Market Cap: C$166.04M
• Dividend Yield: N/A
• Average Volume (3M): 32.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 33
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 35,849,354
• 10 Day Avg. Volume: 30,215
• 30 Day Avg. Volume: 32,164
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$16.61
• Price Target Upside: 264.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Eupraxia Pharmaceuticals faces significant financial challenges with no revenue and high cash burn rates, leading to a low financial performance score. While recent corporate developments show potential for operational progress and improved financial stability, the technical analysis indicates a bearish trend. The stock's valuation remains unattractive due to negative earnings.

Eupraxia Pharmaceuticals Business Overview & Revenue Model

Company Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

How the Company Makes Money

Eupraxia Pharmaceuticals primarily generates revenue through the development and potential commercialization of its drug candidates. The company is focused on advancing its lead product candidates through clinical trials, seeking regulatory approval, and ultimately bringing these products to market. Revenue is expected to be derived from product sales, licensing agreements, and strategic partnerships. Eupraxia may engage in collaborations with larger pharmaceutical companies to co-develop or commercialize its products, thus gaining access to additional resources and market channels. However, as a clinical-stage company, Eupraxia's current revenue is likely limited and largely dependent on funding from investors, grants, or milestone payments from partnerships until its products receive regulatory approval and can be commercialized.

Eupraxia Pharmaceuticals Financial Statement Overview

Summary

Eupraxia Pharmaceuticals is in a growth phase, with initial revenue generation marking a positive step. However, profitability and liquidity issues, coupled with a historically high debt load, present significant challenges. Continued focus on revenue growth and cost management will be vital for future financial health.

Income Statement

Eupraxia Pharmaceuticals has shown a significant improvement in revenue with a TTM figure of $2.98 million, up from zero in previous years, indicating a positive growth trajectory. However, the company is still operating at a substantial loss, with negative net income, EBIT, and EBITDA margins, reflecting ongoing challenges in achieving profitability.

Balance Sheet

The company's debt-to-equity ratio has improved as stockholders' equity turned positive in the recent TTM period. However, the equity ratio is low, and the high historical liabilities indicate potential risk. The improvement in stockholders' equity and reduction in total liabilities are positive signs, but overall financial stability remains a challenge.

Cash Flow

Negative operating and free cash flows highlight liquidity challenges. However, there is an improvement in free cash flow over time, reducing from previous periods. The company has managed financing activities effectively to support cash flow needs, yet the reliance on external financing poses a risk.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.98M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
1.38M	-209.91K	-193.27K	-111.53K	-116.81K	-201.94K
	EBIT
-28.20M	-36.90M	-22.63M	-20.87M	-2.25M	-6.15M
	EBITDA
-20.67M	-37.40M	-22.14M	-21.96M	-2.01M	-5.94M
	Net Income Common Stockholders
-24.20M	-37.39M	-23.26M	-22.99M	-4.00M	-7.18M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.16M	19.34M	24.74M	29.90M	150.13K	1.16M
	Total Assets
3.29M	26.72M	25.88M	31.22M	1.45M	3.29M
	Total Debt
11.94M	10.45M	10.55M	9.56M	12.77M	11.94M
	Net Debt
10.78M	-11.72M	-14.19M	-11.34M	12.62M	10.78M
	Total Liabilities
21.42M	25.55M	14.51M	11.67M	23.12M	21.42M
	Stockholders Equity
-17.69M	2.22M	12.86M	20.39M	-21.21M	-17.69M
Cash Flow		Free Cash Flow
-18.87M	-28.02M	-19.08M	-15.07M	-403.93K	-5.18M
	Operating Cash Flow
-27.03M	-27.92M	-18.78M	-14.64M	-403.93K	-5.17M
	Investing Cash Flow
-65.79K	-99.03K	8.70M	-14.45M	24.62K	-1.90M
	Financing Cash Flow
14.83M	27.84M	13.52M	49.92M	-626.64K	7.40M

Eupraxia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Neutral. The current price of 4.56 is below the 20-day moving average (MA) of 4.57, below the 50-day MA of 5.04, and above the 200-day MA of 4.22, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 46.46 is Neutral, neither overbought nor oversold. The STOCH value of 79.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:EPRX.

Eupraxia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.19B	3.12	-41.08%	2.95%	17.98%	2.02%
EPRX	37 Underperform	C$166.04M	―		―	―	―

Eupraxia Pharmaceuticals Corporate Events

Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress

Eupraxia Pharmaceuticals announced its fourth quarter 2024 financial results, highlighting significant advancements in its RESOLVE trial for eosinophilic esophagitis and a strengthened financial position with a C$44.5 million capital raise. The company reported a reduced net loss due to lower research and development costs and increased cash reserves, positioning it well for continued operations into 2026. Key operational updates included leadership changes and positive trial data, which may enhance its industry standing and stakeholder confidence.

Eupraxia Pharmaceuticals Reports Promising Trial Results for Eosinophilic Esophagitis Treatment

Eupraxia Pharmaceuticals has announced positive results from its RESOLVE Phase 1b/2a trial for EP-104GI, a treatment for eosinophilic esophagitis. The trial showed significant improvements in symptom relief and tissue health, particularly in Cohort 6, with no serious adverse events reported. The data suggests that higher doses and increased esophageal coverage of EP-104GI lead to better outcomes, encouraging further exploration of its potential benefits.